Understanding Tysabri and PML: Key Discussion Points for Care

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Exposure Awareness

If you or someone you care for is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is essential for informed care discussions. This page compiles current research and clinical perspectives to help patients and providers navigate monitoring and risk assessment. Building on a legacy of patient education and informed consent, we present objective information to support your healthcare conversations.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn’s disease (CD) in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients, but Tysabri-treated individuals—even those without overt immunosuppression—have developed the disease. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be subtle and variable. Common early symptoms include progressive weakness, gait disturbance, balance disorder, cognitive impairment, memory loss, and visual changes. These symptoms overlap with those of MS relapses, which can delay diagnosis. FDA adverse-event reports for Tysabri frequently list fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they illustrate the range of neurological symptoms that may be reported by patients, some of which could be early indicators of PML. Diagnosis of PML relies on brain MRI showing characteristic white-matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Brain biopsy may be required in equivocal cases. The prognosis is poor: most patients experience rapid neurological deterioration, and death or severe disability is common. There is no specific antiviral treatment for PML; management focuses on restoring immune function, which in the context of Tysabri means discontinuation of the drug and, in some cases, plasma exchange to accelerate drug clearance.

Legal Considerations and Florida Statute of Limitations

From a legal perspective, patients who develop PML after Tysabri therapy may consider whether the manufacturer provided adequate warnings about the risk. The boxed warning and label clearly state the increased risk of PML and identify the three known risk factors. However, the adequacy of warnings can be challenged if a patient was not adequately informed about the magnitude of risk, the need for regular monitoring, or the importance of early symptom reporting. In Florida, the statute of limitations for personal injury claims related to prescription drugs is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the date of discovery may be the date of diagnosis or the date when symptoms first became clearly attributable to the drug. Given the latency between Tysabri exposure and PML onset—often months to years after starting therapy—the timeline between exposure and documented harm is a critical factor. Patients who received Tysabri for more than two years and who had prior immunosuppressant use are at highest risk, and their claims may be subject to strict time limits. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the date of PML diagnosis, the duration of Tysabri therapy, and any prior immunosuppressant use. The attorney will also assess whether the treating physician followed the TOUCH program requirements and whether the patient was adequately monitored for PML symptoms. In Florida, failure to file within the statute of limitations can bar recovery, so prompt legal evaluation is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims related to prescription drugs is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the date of discovery may be the date of diagnosis or when symptoms first became clearly attributable to the drug. Given the latency between Tysabri exposure and PML onset, prompt legal evaluation is essential to avoid missing the deadline.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with these risk factors should be closely monitored for any signs of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.